A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers.

[1]  B. Burkey,et al.  Locoregional and distant recurrence for HPV-associated oropharyngeal cancer using AJCC 8 staging. , 2020, Oral oncology.

[2]  W. Thorstad,et al.  A prognostic gene expression signature for oropharyngeal squamous cell carcinoma , 2020, EBioMedicine.

[3]  M. Luu,et al.  Comparison of Survival After Transoral Robotic Surgery vs Nonrobotic Surgery in Patients With Early-Stage Oropharyngeal Squamous Cell Carcinoma. , 2020, JAMA oncology.

[4]  E. Mendez,et al.  A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311. , 2020, Oral oncology.

[5]  G. Weinstein,et al.  Retropharyngeal Internal Carotid Artery Management in TORS Using Microvascular Reconstruction , 2020, The Laryngoscope.

[6]  Yoshimi Anzai,et al.  Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[7]  Christopher U. Jones,et al.  NRG-HN002: A Randomized Phase II Trial for Patients With p16-Positive, Non-Smoking-Associated, Locoregionally Advanced Oropharyngeal Cancer , 2019, International Journal of Radiation Oncology*Biology*Physics.

[8]  C. Hurt,et al.  Deintensification of Adjuvant Treatment After Transoral Surgery in Patients With Human Papillomavirus-Positive Oropharyngeal Cancer: The Conception of the PATHOS Study and Its Development , 2019, Front. Oncol..

[9]  J. Rocco,et al.  Margin Analysis in Head and Neck Cancer: State of the Art and Future Directions , 2019, Annals of Surgical Oncology.

[10]  N. Foster,et al.  Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Jing Wang,et al.  Variations in HPV function are associated with survival in squamous cell carcinoma. , 2019, JCI insight.

[12]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial , 2019, The Lancet.

[13]  C. R. Leemans,et al.  Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial , 2019, The Lancet.

[14]  C. Carlson,et al.  The mutational landscape of recurrent versus nonrecurrent human papillomavirus-related oropharyngeal cancer. , 2018, JCI insight.

[15]  Carol Colasacco,et al.  Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists. , 2017, Archives of pathology & laboratory medicine.

[16]  P. Qiu,et al.  Oral Human Papillomavirus Infection: Differences in Prevalence Between Sexes and Concordance With Genital Human Papillomavirus Infection, NHANES 2011 to 2014 , 2017, Annals of Internal Medicine.

[17]  Lihong Qi,et al.  Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. , 2017, The Lancet. Oncology.

[18]  B. Burkey,et al.  Predictors of distant metastasis in human papillomavirus–associated oropharyngeal cancer , 2017, Head & neck.

[19]  Joshua M Bauml,et al.  Transoral Robotic Surgery–Assisted Endoscopy With Primary Site Detection and Treatment in Occult Mucosal Primaries , 2017, JAMA otolaryngology-- head & neck surgery.

[20]  C. Chung,et al.  E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Shah,et al.  Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx. , 2016, Oral oncology.

[22]  I. Ganly,et al.  Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base , 2016, Cancer.

[23]  Shao Hui Huang,et al.  Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. , 2016, The Lancet. Oncology.

[24]  G. Weinstein,et al.  Understanding contraindications for transoral robotic surgery (TORS) for oropharyngeal cancer , 2015, European Archives of Oto-Rhino-Laryngology.

[25]  Wei Xu,et al.  Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[27]  A. Garden,et al.  Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  G. Weinstein,et al.  Transoral robotic surgery: radical tonsillectomy. , 2007, Archives of otolaryngology--head & neck surgery.

[29]  G. Weinstein,et al.  Transoral Robotic Surgery (TORS) for Base of Tongue Neoplasms , 2006, The Laryngoscope.

[30]  M. van Glabbeke,et al.  Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) , 2005, Head & neck.

[31]  P. Rosenberg,et al.  J OURNAL OF C LINICAL O NCOLOGY Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States , 2014 .

[32]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.